LT2635257T - Pasiutligės glikoproteino į virusą panašios dalelės (vlps) - Google Patents

Pasiutligės glikoproteino į virusą panašios dalelės (vlps)

Info

Publication number
LT2635257T
LT2635257T LTEP11838942.8T LT11838942T LT2635257T LT 2635257 T LT2635257 T LT 2635257T LT 11838942 T LT11838942 T LT 11838942T LT 2635257 T LT2635257 T LT 2635257T
Authority
LT
Lithuania
Prior art keywords
vlps
particles
rabies glycoprotein
glycoprotein virus
virus
Prior art date
Application number
LTEP11838942.8T
Other languages
English (en)
Inventor
Gale Smith
Ye Liu
Original Assignee
Novavax, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novavax, Inc. filed Critical Novavax, Inc.
Publication of LT2635257T publication Critical patent/LT2635257T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
LTEP11838942.8T 2010-11-05 2011-11-07 Pasiutligės glikoproteino į virusą panašios dalelės (vlps) LT2635257T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41076710P 2010-11-05 2010-11-05
PCT/US2011/059602 WO2012061815A2 (en) 2010-11-05 2011-11-07 RABIES GLYCOPROTEIN VIRUS-LIKE PARTICLES (VLPs)

Publications (1)

Publication Number Publication Date
LT2635257T true LT2635257T (lt) 2017-09-25

Family

ID=46025156

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP11838942.8T LT2635257T (lt) 2010-11-05 2011-11-07 Pasiutligės glikoproteino į virusą panašios dalelės (vlps)

Country Status (21)

Country Link
US (3) US9724405B2 (lt)
EP (2) EP3246019B1 (lt)
JP (2) JP6158088B2 (lt)
KR (1) KR101847908B1 (lt)
CN (2) CN103282023B (lt)
AU (1) AU2011323090B2 (lt)
BR (1) BR112013011194B1 (lt)
CA (1) CA2817005C (lt)
CY (1) CY1119284T1 (lt)
DK (1) DK2635257T3 (lt)
ES (1) ES2636965T3 (lt)
HR (1) HRP20171213T1 (lt)
HU (1) HUE034247T2 (lt)
LT (1) LT2635257T (lt)
MX (1) MX354750B (lt)
PL (1) PL2635257T3 (lt)
PT (1) PT2635257T (lt)
RS (1) RS56157B1 (lt)
SG (1) SG190140A1 (lt)
SI (1) SI2635257T1 (lt)
WO (1) WO2012061815A2 (lt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2615372A1 (en) 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
PT2610345E (pt) 2007-11-27 2016-01-11 Medicago Inc Partículas semelhantes ao vírus (vlps) da gripe recombinantes produzidas em plantas transgénicas que expressam hemaglutinina
HUE051666T2 (hu) 2008-12-09 2021-03-29 Novavax Inc Módosított RSV F fehérjék és alkalmazásuk módszerei
US11446374B2 (en) 2008-12-09 2022-09-20 Novavax, Inc. Modified RSV F proteins and methods of their use
PT3354657T (pt) 2009-09-22 2022-05-06 Medicago Inc Método de preparação de proteínas derivadas de plantas
AU2011323090B2 (en) 2010-11-05 2015-02-12 Novavax Inc. Rabies glycoprotein virus-like particles (VLPs)
TWI620816B (zh) 2011-03-23 2018-04-11 苜蓿股份有限公司 植物衍生蛋白回收方法
ES2665512T3 (es) * 2011-06-13 2018-04-26 Medicago Inc. Producción de partículas pseudovíricas de la rabia en plantas
KR101479668B1 (ko) 2012-07-31 2015-01-12 대한민국 광견병 바이러스 유전자를 발현하는 재조합 아데노바이러스 및 이를 포함하는 광견병의 예방 또는 치료용 백신 조성물
CN103777021B (zh) * 2012-10-18 2016-03-02 辽宁成大生物股份有限公司 狂犬疫苗糖蛋白含量的检测方法
CN114796474A (zh) 2015-09-03 2022-07-29 诺瓦瓦克斯股份有限公司 具有改进的稳定性和免疫原性的疫苗组合物
CN106905434B (zh) * 2017-02-28 2021-01-26 国药中生生物技术研究院有限公司 一种包含蹄蝠肝炎病毒核心蛋白的重组融合蛋白及其制备方法和应用
EP3420076B1 (en) * 2017-03-06 2024-02-21 Guangzhou Realbenefitspot Pharmaceutical Co., Ltd. Methods of producing and characterizing virus vaccine and virus vaccine composition
WO2018161858A1 (en) 2017-03-06 2018-09-13 Guangzhou Realbenefitspot Pharmaceutical Co., Ltd. Methods of producing and characterizing virus vaccine and virus vaccine composition
AU2018360288A1 (en) * 2017-11-06 2020-05-07 Intervet International B.V. Rabies virus vaccine
AU2019238171A1 (en) 2018-03-19 2020-09-24 Novavax, Inc. Multivalent influenza nanoparticle vaccines
KR102077772B1 (ko) 2018-11-29 2020-02-17 주식회사 바이오앱 광견병 예방용 백신 조성물 및 이의 제조 방법
KR102211077B1 (ko) * 2019-01-16 2021-02-02 충남대학교 산학협력단 바이러스 유사 입자를 이용한 슈도-타입 광견병 백신
CN109959789B (zh) * 2019-04-12 2022-08-16 长春西诺生物科技有限公司 一种狂犬病毒抗体检测试纸及其制备方法与检测方法
CN110007080B (zh) * 2019-04-12 2022-09-23 长春西诺生物科技有限公司 一种狂犬病毒抗体定量检测试剂盒及其制备方法与检测方法
WO2023064931A1 (en) * 2021-10-15 2023-04-20 La Jolla Institute For Immunology Engineered rabies virus glycoprotein, compositions, and methods of use thereof
CN114272367B (zh) * 2021-12-03 2023-07-07 华东理工大学 一种口服狂犬病病毒样颗粒疫苗及其制备方法
KR102566969B1 (ko) 2021-12-14 2023-08-16 안희철 근거리 통신 과정에서 충전 가능한 모바일 단말

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0237686A1 (en) * 1986-03-18 1987-09-23 Institut Pasteur DNA sequences derived from the rabies virus genome
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US5667782A (en) * 1992-07-16 1997-09-16 Oxford University Multiple particulate antigen delivery system
US6387373B1 (en) 1993-01-15 2002-05-14 Novavax, Inc. Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants
US5629021A (en) 1995-01-31 1997-05-13 Novavax, Inc. Micellar nanoparticles
US6589533B1 (en) * 1997-09-18 2003-07-08 Research Development Foundation Genetically-engineered alphaviruses, flaviviruses, and bunyaviruses with modified envelope transmembrane glycoproteins and altered host-range phenotype
US6673601B1 (en) * 1999-04-15 2004-01-06 Institut Pasteur Chimeric lyssavirus nucleic acids and polypeptides
AUPR011700A0 (en) * 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
EP1460992B1 (en) * 2001-12-03 2009-03-11 Dor Biopharma, Inc. Stabilized reverse micelle compositions and uses thereof
US7211378B2 (en) * 2002-01-31 2007-05-01 Wisconsin Alumni Research Foundation Filovirus vectors and noninfectious filovirus-based particles
US20040063188A1 (en) 2002-02-14 2004-04-01 Novavax, Inc. Kit for treating gastrointestinal tract
US8592197B2 (en) * 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US9216212B2 (en) * 2005-08-05 2015-12-22 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
CA2636600A1 (en) * 2006-01-17 2007-07-26 Dnavec Corporation Novel protein expression system
WO2007144886A2 (en) * 2006-06-15 2007-12-21 Ben-Gurion University Of The Negev Research And Development Authority Virus-like particles for treatment of viral infections
EP2035565A4 (en) 2006-06-30 2010-07-21 Novavax Inc METHODS OF ENHANCING THE INCORPORATION OF PROTEINS IN VIRUS-LIKE PARTICLES (VLPs)
US8980281B2 (en) * 2006-09-05 2015-03-17 Academia Sinica High-yield transgenic mammalian expression system for generating virus-like particles
TW200907058A (en) * 2007-05-30 2009-02-16 Wyeth Corp Raccoon poxvirus expressing rabies glycoproteins
RU2010105858A (ru) * 2007-07-19 2011-08-27 Новавакс, Инк. (Us) Вирусоподобные частицы (vlp) вируса varicella zoster и антигены
KR100961280B1 (ko) * 2008-05-21 2010-06-03 한국생명공학연구원 형광특성이 향상된 풀러렌-실리카 나노입자, 이의 제조방법및 이의 용도
WO2009153801A1 (en) * 2008-06-17 2009-12-23 Manpreet Kaur Dna vaccine based on glycoprotein gene of rabies virus conjugated to lamp-1 signal sequence at the c-terminus and an adjuvant; and method of its preparation thereof
WO2010040023A2 (en) * 2008-10-03 2010-04-08 Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods and compositions for protein delivery
HUE051666T2 (hu) 2008-12-09 2021-03-29 Novavax Inc Módosított RSV F fehérjék és alkalmazásuk módszerei
AU2011323090B2 (en) * 2010-11-05 2015-02-12 Novavax Inc. Rabies glycoprotein virus-like particles (VLPs)

Also Published As

Publication number Publication date
JP2017035093A (ja) 2017-02-16
CA2817005C (en) 2018-09-11
ES2636965T3 (es) 2017-10-10
US20180021428A1 (en) 2018-01-25
EP2635257B1 (en) 2017-07-05
HRP20171213T1 (hr) 2017-10-20
KR101847908B1 (ko) 2018-04-11
WO2012061815A3 (en) 2013-03-14
US20190224307A1 (en) 2019-07-25
WO2012061815A2 (en) 2012-05-10
US20140178419A1 (en) 2014-06-26
CN103282023A (zh) 2013-09-04
PL2635257T3 (pl) 2017-10-31
RS56157B1 (sr) 2017-11-30
EP3246019A1 (en) 2017-11-22
MX354750B (es) 2018-03-20
CN109157658A (zh) 2019-01-08
AU2011323090A1 (en) 2013-04-04
EP3246019B1 (en) 2021-03-03
JP2014500013A (ja) 2014-01-09
EP2635257A2 (en) 2013-09-11
SI2635257T1 (en) 2018-01-31
CA2817005A1 (en) 2012-05-10
US10086065B2 (en) 2018-10-02
JP6195965B2 (ja) 2017-09-13
SG190140A1 (en) 2013-06-28
PT2635257T (pt) 2017-08-16
KR20130111581A (ko) 2013-10-10
CN103282023B (zh) 2018-09-21
DK2635257T3 (en) 2017-09-04
RU2013125695A (ru) 2014-12-10
AU2011323090B2 (en) 2015-02-12
BR112013011194B1 (pt) 2020-12-22
JP6158088B2 (ja) 2017-07-05
MX2013005090A (es) 2013-10-25
EP2635257A4 (en) 2014-04-02
US9724405B2 (en) 2017-08-08
CY1119284T1 (el) 2018-02-14
BR112013011194A2 (pt) 2017-06-27
HUE034247T2 (en) 2018-02-28

Similar Documents

Publication Publication Date Title
RS56157B1 (sr) Glikoproteinske čestice nalik virusu (vlp) besnila
HRP20180706T1 (hr) Kimerna gripa nalik čestici koja sadrži hemaglutinin
IL210215A0 (en) Influenza virus-like particles (vlps) comprising hemagglutinin
EP2536428A4 (en) UNIVERSAL INFLUENZA VACCINES WITH VIRUSIC PARTICLES
EP2242510A4 (en) PSEUDO-VIRAL PARTICLES AS VACCINES FOR PARAMYXOVIRUS
HK1202442A1 (en) Vaccines against hpv hpv
HK1198703A1 (en) Hpv chimaeric particle hpv
EP2538969A4 (en) VACCINES FROM POLYSACCHARIDE PARTICLES
HK1203837A1 (en) Immunogenic hpv l2-containing vlps and related compositions and methods hpv l2 vlp
HK1200179A1 (en) Increasing virus-like particle yield in plants
EP2707480A4 (en) PSEUDOVIRAL PARTICLES (VLPs) AND PREPARATION METHOD THEREOF
EP2588135A4 (en) NANO EMULSION VACCINES
SI2739725T1 (sl) Postopek za čiščenje od virusov-podobnih delcev
EP2400982A4 (en) MULTI-ANTIGEN RELIEF SYSTEM WITH HEPATITIS E-VIRUS SIMILAR PARTICLE
EP2585598A4 (en) PAN-LYSSAVIRUS VACCINES AGAINST TOLLWUT
EP2881401A4 (en) EXTREMELY EFFICIENT METHOD OF PURIFYING VIRAL PSEUDO PARTICLES OF HUMAN PAPILLOMAVIRUS
IL220941A0 (en) Method for producing recombinant virus
IL226187B (en) Virus-like glycoprotein particles in rabies